The historical rank and industry rank for Amicus Therapeutics's Net Margin % or its related term are showing as below:
FOLD'
s Net Margin % Range Over the Past 10 Years
Min: -4034.73 Med: -106.12 Max: -10.62
Current: -10.62
FOLD's Net Margin % is ranked better than 69.33% of 1001
companies
in the Biotechnology industry
Industry Median: -132.46
vs FOLD: -10.62
Amicus Therapeutics Net Margin % Historical Data
The historical data trend for Amicus Therapeutics's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Amicus Therapeutics's Net Margin %
For the Biotechnology subindustry, Amicus Therapeutics's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Amicus Therapeutics's Net Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Amicus Therapeutics's Net Margin % distribution charts can be found below:
* The bar in red indicates where Amicus Therapeutics's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Amicus Therapeutics (NAS:FOLD) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Amicus Therapeutics Net Margin % Related Terms
Thank you for viewing the detailed overview of Amicus Therapeutics's Net Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FOLD has been successfully added to your 